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Abstract 
Neuro-immune interactions may contribute to severe pain, and regional inflammatory and 
autonomic signs in Complex Regional Pain Syndrome (CRPS). However, the pathophysiological 
mechanisms remain unclear and therapies are unsatisfactory. Here we investigated peripheral and 
central immune mechanisms in a passive transfer-trauma translational mouse model of CRPS, 
where small plantar skin-muscle incision was performed in female C57Bl/6 mice treated daily 
with purified serum-IgG from patients with longstanding CRPS, or healthy volunteers. CRPS 
IgG significantly increased and prolonged swelling, and induced stable hyperalgesia of the 
incised paw compared to IgG from healthy patients. Following a short-lasting paw inflammatory 
response in all groups, CRPS mice displayed sustained microglia and astrocyte activation in the 
dorsal horn of the spinal cord and in pain-related brain regions, indicating central sensitization. 
Genetic deletion of interleukin-1 (IL-1) using IL-1Įȕ.2PLFH and perioperative IL-1 receptor 
type 1 (IL-1R1) blockade with the drug anakinra, but not steroid treatment precluded the 
development of transferred CRPS. Anakinra treatment also abrogated the established 
sensitization phenotype when initiated 8 days after incision. Furthermore, with the generation of 
a novel IL-ȕfl/fl mouse line, we demonstrated that these actions are in part mediated by 
microglia-derived IL-ȕ, suggesting that both peripheral and central inflammatory mechanisms 
contribute to the transferred CRPS phenotype. These results indicate that persistent CRPS is 
mediated by autoantibodies and highlight a novel therapeutic use for clinically licensed 
antagonists, such as anakinra, to prevent or treat CRPS via blocking IL-1 actions. 
 
Significance statement: Severe chronic pain is a common health problem, which can 
profoundly affect the quality of life for patients. Currently, the mechanisms of chronic pain are 
not completely understood and there are few pain-relieving drug treatments that are effective 
long-term. In this study we show that serum autoantibodies from patients with a severe, 
posttraumatic chronic pain condition, but not serum autoantibodies from healthy controls, cause 
long-lasting unilateral paw hypersensitivity in mice after acute hind-paw injury, mimicking the 
clinical condition. These symptoms can be prevented by blocking the actions of the 
proinflammatory mediator, interleukin-1 (IL-1) with the drug anakinra, which is licensed for 
clinical use. Our findings show that antibody-mediated autoimmunity contributes to the 
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development of severe chronic pain after injury and that blockade of IL-1 actions is 
therapeutically effective. 
 
 
INTRODUCTION 
 
Complex Regional Pain Syndrome (CRPS), with a prevalence of about 1:2000, is a severe 
chronic pain experienced by humans. CRPS is usually triggered by trauma to the distal regions of 
a limb, and is further associated with limb-restricted sensory, motor, autonomic, and trophic 
abnormalities, and profound sensory central nervous system (CNS) reorganisation. In CRPS no 
or only minimal tissue destruction occurs (1, 2).  The pathophysiological mechanisms underlying 
CRPS are poorly understood. Systemic inflammatory markers remain normal in CRPS patients, 
but regional inflammatory mediators and autoimmunity are suggested to contribute to the 
manifestation of the symptoms (1, 3). Furthermore, neuro-plasticity mechanisms within the 
spinal cord and the brain are believed to sustain persistent pain and associated cognitive and 
emotional changes (2, 4, 5). 
While most patients with CRPS show an improvement within months, either with or without 
treatment (6), 1 in 5 patients develop persistent pain, often lasting years or even through their 
lifetime (7). This type of persistent pain is intrusive and results in amongst the lowest quality of 
life scores in medical conditions (8). Among the few drug trials performed to date (9) neither 
conventional drugs used to relieve pain, such as non-steroidal anti-inflammatory drugs, opioids, 
anti-depressants, or anti-epileptics (10), nor steroids (11, 12) have shown significant efficacy in 
persistent CRPS. Implantation of a spinal cord stimulator, which delivers electrical impulses to 
the dorsal column can over-ride CRPS pain in about 50% of the patients (13), but the duration of 
the optimum effect is limited to a few years (14). Since many patients cannot be successfully 
treated (7, 15), the treatment of CRPS remains an important unresolved problem and is still an 
unmet medical need (16). Thus, to better understand the peripheral and central 
pathophysiological mechanisms underlying CRPS, reliable and validated animal models are 
desperately needed (16, 17). 
We have recently shown that passive transfer of serum-IgG from CRPS patients to hindpaw-
injured rodents elicits key features (unilateral hyperalgesia and edema) of the clinical condition 
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(18). This suggests a 2-hit pathology, where circulating IgG autoantibodies are rendered 
pathogenic in the context of paw injury-related regional or central modifications (3). Although 
these behavioural results indicated that serum IgG autoantibodies contribute to the disease 
pathophysiology, and thus provided the first evidence for the construct-validity of the transfer 
model, the observed abnormalities were modest-sized and short-lasting, and the mechanisms 
mediating them remain unknown. 
Using samples available from patients who consented to repeat donation of larger blood 
volumes, or who had received plasma exchange treatment (19, 20), we have now developed an 
enhanced passive IgG transfer-trauma model, and have examined its translational validity. We 
investigated, i) whether and how transferred behavioural signs are augmented and sustained to 
resemble the clinical phenotype, and whether there are differences between preparations from 
different patients, ii) the degree of regional post-traumatic immune activation in the paw, given 
that mild, transient immune activation in the affected skin is sometimes detected in patients (21), 
and its correlation to behavioural parameters, iii) the degree and mechanisms of post-traumatic 
glial activation in the spinal cord since strong CNS re-organisation is recognized in the clinical 
cases (4, 22), and finally iv) whether targeting specific inflammatory pathways at the time of, or 
after trauma can prevent or treat transferred CRPS (tCRPS) to provide a translatable therapeutic 
approach.  
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RESULTS 
 
Daily administration of serum IgG from CRPS patients induces profound and persistent 
post-incisional mechanical hyperalgesia. 
The pre-operation mechanonociceptive threshold values of the affected limbs were 8.65 + 0.08, 
8.69 + 0.09 and 8.60 + 0.07 in the saline, healthy IgG- and CRPS IgG-treated mice, respectively 
(not significantly different, Fig. 1A). Plantar skin and muscle incision induced a 45-50 % relative 
decrease of the mechanonociceptive threshold in all groups 1 day after the surgery. Upon daily 
injections, paw sensitivity quickly recovered to mild hyperalgesia in both saline and healthy IgG 
injected animals, with mild, non-significantly enhanced values remaining in the healthy IgG 
group versus the saline group throughout the experimental period. Injection of IgG from CRPS 
patients caused significantly augmented hyperalgesia compared to IgG from healthy volunteers, 
which appeared to be further enhanced towards the end of the experimental period. This effect 
was evident in the IgG preparations from each individually tested patient (n=7), as well as a 
preparation pooled from 7 separate patients (Fig. 2, supplementary appendix Fig. S2). The 
observed 15-32% absolute threshold reduction was two-fold compared to that seen in our 
previously published experimental model (injections on day -1, 0, 5, 6) (18). Contralateral paws 
retained normal sensitivity in all groups (supplementary appendix Fig.S1). Post-surgical weight 
loss compared with baseline reached a nadir at days 3-4, and the weights of the animal then fully 
recovered, without significant differences between groups (supplementary appendix Fig. S0). We 
observed no spontaneous nocifensive behaviours, such as paw biting, lifting, licking. 
 
In all groups, injured paws developed about 30% relative paw swelling (defined as edema) on 
day 1, but there were no changes in contralateral paws (supplementary appendix Fig. S1). Edema 
resolved in healthy IgG and saline groups, but CRPS IgG injection significantly slowed edema 
resolution (Fig. 1B). Whereas the pattern of transferred hyperalgesia was uniform, there was 
important variability in the degree and pattern of transferred swelling between different patient 
preparations, with no correlation between these two parameters (Fig. 2, supplementary appendix 
Figs. S2-3). Minimal weight loss was observed with a nadir on days 3-4 post surgery and no 
difference between injection groups (supplementary appendix Fig. S0).  
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Figure 1 
 
 
Fig. 1. Effect of intraperitoneal injection of serum IgG derived from complex regional pain syndrome (CRPS) 
patients or healthy controls on plantar incision-induced mechanical hyperalgesia (A) and swelling (B) of the injured 
mouse hindpaw. IgG was administered daily, starting on day 0. The right hindpaws were incised on day 0, about 6 h 
after immunoglobulin injection. Shown are pooled results from all three long-term experiments to either day 10 or 
day 13, with three different IgG preparations (#2, 3, 4) (see patients details in supplementary Table S1, individual 
results in Figure 2). Data are means + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 (vs. saline-treated control mice), #p 
< 0.05, ###p < 0.001 (vs. healthy IgG-treated mice); two-ZD\ $129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH
comparison test. 
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Figure 2 
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Fig. 2. Individual preparations elicit consistent, stable mechanical hyperalgesia, but variable paw swelling. Panels 
show behavioural data in groups of animals injected with either of four IgG preparations (patients #1,2,3,4), 
demonstrating patient/preparation-dependent variations and apparent lack of correlation between hyperalgesia (A, C, 
E, G) and paw edema (B, D, F, H). Data are shown as means + SEM, *p < 0.05, **p < 0.01, ***p < 0.001 (vs. 
saline-treated control mice), #p < 0.05, ###p < 0.001 (vs. healthy IgG-treated mice); two-way ANOVA followed by 
%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW  
 
CRPS IgG does not alter vascular plasma leakage, but increases neutrophil MPO activity 
early after paw incision  
Indocyanin green (ICG) - derived fluorescence showed a trend to increase in the injured paws in 
all groups two days after paw incision emphasising that CRPS-IgG did not specifically affect 
plasma-extravasation (saline injured: 1.52 x 109 + 1.11 x 108; healthy IgG injured: 1.42 x 109 + 
1.54 x 108; CRPS IgG injured: 1.70 x 109 + 2.2 x 108; fluorescence intensity: 
(photons/second/cm2/steradian)/PW/cm2). 
 As expected, in vivo imaging of L-012 derived bioluminescence, used as a sensitive marker of 
inflammatory cell activity (most prominently neutrophil-derived MPO) showed increased signal 
in response to limb trauma alone (Fig.3). We found significantly increased neutrophil MPO-
activity in the CRPS IgG-treated animals on the affected side 2 days after the incision, when 
compared to the control groups. Differences in MPO-activity in CRPS IgG versus healthy IgG 
groups had disappeared by day 6, although significant increases in the injured paw were still 
present compared to the intact side on day 13. Importantly, while strong variability was seen 
between different IgG preparations in influencing MPO-activity (Supplementary Fig. S4 and 
Table S1), bioluminescence measured on day 2 or 6 did not correlate with either maximal paw 
swelling or hyperalgesia on day 6 (not shown). This suggests that altered MPO activity in the 
injured paw of tCRPS mice is an unrelated IgG effect that is unlikely to explain the marked 
impact of CRPS IgG on paw hypersensitivity. 
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Figure 3 
 
 
 
Fig. 3. Imaging reactive oxygen species demonstrates the development of inflammation in the injured hindpaws of 
mice. In vivo images of L-012 - derived bioluminescence were obtained during general anaesthesia on days 2, 6 and 
13 after paw incision. Typical images are shown in (A), and quantification of the bioluminescence-intensity in (B). 
Data at each time point represent the pooled results from experiments conducted with separate CRPS/healthy IgG 
preparations (number of preparations per time point in brackets, details in the supplementary appendix Figure S4 
and Table S2), and are shown as means + SEM of n= 6-18 mice/group; *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
respective control groups, #p < 0.05, ##p < 0.01 vs. respective intact side, one-way ANOVA followed by 
%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW. 
 
CRPS IgG does not promote inflammation or neuropathy in the paw 
We further examined whether the tCRPS behavioural signs related to locally augmented 
inflammatory responses, or to neuropathic changes. In successive experiments, animals were 
sacrificed between experimental days 1-13 and paw tissues harvested to assess various 
inflammatory changes (animal numbers and preparations supplementary Table S3).  
Substance P (SP) levels increased in the injured paw, with higher levels in the CRPS IgG group 
on day 6 (Fig. 4A), while calcitonin gene related peptide (CGRP) levels were not significantly 
altered (Fig. 4B), consistent with earlier findings (18). Increased levels of inflammatory 
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mediators were seen in the injured paws, with gradual decrease over time (shown in Figure 4C-F 
for interleukin-6 (IL- WXPRU QHFURVLV IDFWRU Į 71)-Į PRQRF\WH FKHPRDWWUDFWDQW SURWHLQ-1 
(MCP-1), interleukin-1 (IL-ȕDQGIRUDGGLWLRQDOPHGLDWRUVLQWKHVXSSOHPHQWDU\DSSHQGL[6. 
We detected no differences in the levels of inflammatory mediators between the CRPS and 
healthy IgG groups (Figure 4C-F, supplementary appendix S5) at any time point, except for a 
mild CRPS-IgG induced MCP-1 increase at day 13 (Fig. 4E). Notably, at the time of maximum 
hyperalgesia, 13 days post-injury, most mediators were undetectable. There were no significant 
changes in plasma concentrations of any cytokines after correction for multiple testing 
(supplementary appendix Fig. S6). 
Histological examination revealed moderate infiltration of inflammatory cells into areas 
immediately adjacent to the incision early after surgery, with no obvious difference between 
groups, and no evidence of infiltration by inflammatory cells on day 13 in any experimental 
group (not shown). Since some patients with persistent CRPS exhibit mild small fibre 
neuropathy (23), we also examined mouse paws for any evidence of structural changes to small 
skin nerves with both light- and electron microscopy. The morphology of the axons in the right 
and left paws and the ultrastructure of non-myelinated and thinly-myelinated axons were very 
similar between experimental groups (Figure 5). 
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Figure 4 
 
Fig. 4. Effects of human IgG treatments on sensory neuropeptide and inflammatory cytokine concentrations in the 
hindpaws. Concentrations of (A) SP and (B) CGRP were measured by radioimmunoassay in hindpaw homogenates 
excised after sacrifice. Concentrations of (C) IL-6, (D) TNF-Į, (E) MCP-1 and (F) IL-1ȕ were measured by 
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cytometric bead array from the same samples. Data are from 1-3 experiments per time point (bracket below x-axis) 
each with different patient preparations. Shown are means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 respective 
control groups, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. respective intact side, one-way ANOVA followed by 
%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW. 
 
Figure 5 
 
 
 
Fig. 5. Small nerve fibres in the tCRPS paw skin. (A-D) Semithin sections of the right (A, C) and left (B, D) paws of 
the CRPS group. Arrows point to bundles containing non-myelinated, thinly-myelinated and myelinated axons. 
Structures shown in (A, B) are visible in (C, D) with higher magnification. Scale bar is 50 µm in (A, B), 20 µm in 
(C, D). (E-I) Photomicrographs of ultrathin transmission EM sections of the right (E, G, I) and the left (F, H) paws 
of the CRPS group. (E, F) show small magnification images of thin nerves containing non-myelinated, thinly-
myelinated and myelinated axons. (G) Ultrastructure of non-myelinated axons (asterisks), and (I) of a thinly-
myelinated axon in an oblique section (arrow). (H) Ultrastructure of non-myelinated axons (asterisks) from the left 
paw. Scale bar is 3 µm in (E, F), 500 nm in (G, H) and 750 nm in (I). 
 
CRPS-IgG facilitates sustained microglia activation in the CNS  
We next investigated, whether altered activity of microglia or astrocytes in pain-related circuits 
(24) would reflect the marked effects of CRPS IgG on pain sensitivity responses. Glial cell 
counts showed a trend to increase in the ipsilateral dorsal horn and the contralateral S1 cortex at 
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all time points when compared to the respective mirror sides, which did not always reach 
significance (Fig. 6 and Fig. S7). 
In CNS areas receiving input from the injured paw, CRPS-IgG induced remarkable increases in 
both astrocyte and microglia cell numbers when compared to both saline and healthy IgG groups. 
In the dorsal horn, this response was sometimes much stronger than the increases representing 
the incision trauma (Fig. 6). Astrocyte reactivity in the CRPS IgG animals was augmented in all 
CNS areas at early time points (day 3 and day 6), whereas microglia staining was enhanced 
throughout the experimental period including day 13 (Fig. 6 and Fig. S7). This highlights that 
increased mechanical hypersensitivity in this CRPS model is associated with transient astrocyte-, 
and persistent microglial activation in the CNS. 
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Figure 6 
 
 
 
Fig. 6. Glial activation in the L5 spinal cord dorsal horn, ipsilateral to the paw injury. Panels (A-C) show GFAP 
immunopositivity marking astrocytes, and panels (G-I) show Iba1 immunopositivity marking microglia cells, with 
(A, G) saline, (B, H) healthy, and (C, I) CRPS. The GFAP immunopositive sections shown are from day 6-, and 
Iba1 sections from day 13 after paw incision. Quantification of astrocyte reactivity (D-F) and microglia staining (J-
L) in lamina I-II dorsal horn of the L4-L6 spinal cord, and deeper laminae, at 3, 6, and 13 days post hindpaw 
incision. Each panel represents the pooled results from 2 experiments with 2 different samples (#3, #4). Shown are 
means ± SEM of 6-7 mice per group *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups; #p< 0.05, 
##p< 0.01, ###p< 0.001 vs. respective contralateral side; one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPRGLILHGSRVW
hoc test. 
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Early IL-1 receptor blockade with anakinra prevents the development of tCRPS, while 
delayed anakinra treatment abrogates established tCRPS and reduces glial activation.   
Since both microglia and astrocytes are important sources of proinflammatory cytokines that are 
known to contribute to pain hypersensitivity responses (25, 26) and as interleukin-1 is a key 
mediator that influences neuronal activity (27, 28), we investigated the effects of steroid 
treatment, or interleukin-1 receptor antagonist treatment (anakinra) on CRPS-IgG induced 
behavioural signs and inflammatory changes. Prednisolone (4 mg/kg), or anakinra (10 mg/kg) 
were daily administered intraperitoneally, starting 5h prior to surgery (day 0) and extending 
throughout the experimental period. One day after surgery, mechanical hyperalgesia developed 
equally in all groups (Fig. 7. A-B). Steroid treatment transiently reduced CRPS-IgG induced 
mechanical hyperalgesia (between days 2 and 3), but behaviour had reverted to the abnormal 
course by day 7. In contrast, anakinra prevented all CRPS-IgG-induced effects throughout the 
experimental period (Fig.7B). Anakinra, but not steroid treatment almost completely reversed 
glia cell activation in the ipsilateral dorsal horn, on day 6 (Figure 7. D-E); notably anakinra 
treatment also significantly reduced paw MCP1 levels on day 3, but there were no other 
differential effects on peripheral mediator production between these two treatments (appendix 
Fig. S7). Delayed administration of anakinra from day 8 onwards abrogated the established 
tCRPS phenotype (Figure 7C), and completely reversed the associated increased dorsal horn 
microglia activation on day 13 (7F). 
 
Figure 7 
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Fig. 7. Effects of prophylactic steroid or anakinra treatment (days 0-6), and delayed (therapeutic) anakinra 
treatment on CRPS-IgG induced mechanical hyperalgesia, and glial activation in the spinal cord. Panels (A, B) 
show mechanical hyperalgesia in groups of animals injected intraperitoneally first with human IgG or saline, and 3 
hours later with 4 mg of prednisolone or 10 mg/kg anakinra, or saline vehicle, on each day between days 0-6. Panels 
(D, E) show dorsal horn glia cell activation in these mice on day 6, (D): GFAP (astrocyte); (E): Iba-1 (microglia). 
Results represent the average values derived from two independent experiments with different preparations for each 
treatment, four experiments in total; saline, healthy, and CRPS outcomes are pooled from these experiments. (C, F) 
- late anakinra treatment starting day 8, C - behavioural outcome, (F) - dorsal horn microglia cell count on day 13. 
Data are shown as means + SEM. Significance symbols for the behavioural data: *p < 0.05, **p < 0.01, ***p < 
0.001 (CRPS vs. saline-treated control mice), #p < 0.05, ###p < 0.001 (CRPS vs. healthy IgG-treated mice), +++p < 
0.001 (anakinra + CRPS vs. CRPS IgG-injected mice), two-ZD\ $129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH
comparison test.  
Significance immunohistochemistry data: *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups; #p< 0.05, 
##p< 0.01, ###p< 0.001 vs. respective contralateral side; one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPRGLILHGSRVW
hoc test. 
 
Selective deletion of microglial IL-1ȕ DPHOLRUDWHV ZKLOH XELTXLWRXV GHOHWLRQ RI ,/-Įȕ
completely prevents tCRPS.   
As these results indicated that blockage of IL-1 reverses the tCRPS phenotype, and since CRPS 
IgG did not appear to enhance paw IL-1 but caused significant dorsal horn glia cell activation, 
we investigated whether tCRPS was associated with enhanced dorsal horn glia cell IL-1 
production as a potential target in the observed effects of anakinra treatment. We detected IL-1E 
in L4/L5 dorsal horn microglia cells only in the tCRPS group (Figure 8A), while IL-1Dwas not 
detected (not shown). We then examined, whether the tCRPS phenotype would be altered by 
genetic knockout of IL-1. We found that CRPS IgG injected IL-Įȕ .2 PLFH developed no 
enhanced hyperalgesia, and showed even less post-traumatic paw swelling (Figure 9 B-C) than 
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mice treated with healthy IgG. To investigate whether increased microglial IL-ȕSURGXFWLRQLV
sufficient to mediate the effects of CRPS IgG on increased mechanical hyperalgesia, we 
generated a novel IL-ȕfl/fl mouse line. Exon 4-5 of the IL-ȕJHQHZDVflanked with loxP sites, 
resulting in the generation of IL-1ȕfl/fl allele (Supplementary Fig. S9). IL-1ȕfl/fl mice were crossed 
with Cx3cr1CreER mice (29) resulting in microglial deletion of IL-ȕ XSRQ WDPR[LIHQ
administration (M-IL-1E KO), while most peripheral Cx3cr1-positive cells recovered IL-ȕ
production due to their higher turnover as shown by using other cre-dependent reporter lines 
previously (29). In fact, IL-ȕSURWHLQOHYHOVwere markedly reduced in IL-ȕ.2 microglia after 
repeated intraperitoneal injections of bacterial LPS compared to WT microglia, but no changes 
were seen in splenic macrophages derived from tamoxifen-treated Cx3cr1CreER x IL-1ȕfl/fl mice 
compared to controls (Supplementary Fig. S10). Elimination of microglial IL-ȕ significantly 
reduced mechanical hyperalgesia and paw edema in mice treated with CRPS IgG, although this 
effect was smaller than in the case of IL-Įȕ KO mice (Fig. 8B-C). Total numbers of microglia 
were reduced in IL-Įȕ.2PLFHEXWZHUHnot altered in response to microglial IL-ȕGHOHWLRQLQ
the CRPS group (Fig.9D), suggesting that while microglial IL-ȕ is an important driver of 
chronic neuro-inflammation contributing to persistent pain, other IL-ȕ-producing cells or 
actions mediated by IL-ĮFRXOGDOVRFRQWULEXWHWR&536V\PSWRPVLQPLFH 
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Figure 8 
 
 
Fig. 8. Deletion of IL-Įȕ RU PLFURJOia-derived IL-ȕ fully or partially prevents development of the tCRPS 
phenotype in mice. (A): A population of microglia display a morphologically activated phenotype and show 
immunopositivity for IL-ȕ at day 7 in deep laminae of the L4-L5 spinal cord near the central canal; scale bar: 
ȝP (B, C) IL-Įȕ.2PLFHDUHfully-, and M-IL-1ȕKO are partially protected from the development of tCRPS; 
(B) paw hyperalgesia, (C) paw edema. (D) CRPS IgG induced microglia activation is abrogated in IL-Įȕ.2EXW
not M-IL-1ȕKO mice (30).  
Data are pooled from two experiments with different CRPS IgG preparations for each mouse type and are shown as 
means + SEM. Significance in (B, C): *p < 0.05, **p < 0.01, ***p < 0.001 (CRPS WT vs. healthy WT), #p < 0.05, 
###p < 0.001 (CRPS M-IL-ȕ KO/ CRPS IL-Įȕ KO vs CRPS WT), +p < 0.05, ++p < 0.01, +++p < 0.001 (CRPS IL-
Įȕ KO vs. CRPS M-IL-ȕ KO), two-ZD\ $129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH FRPSDULVRQ WHVW
Significance values in (D): *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups; #p< 0.05, ##p< 0.01, 
###p< 0.001 vs. respective contralateral side; one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPRGLILHGSRVWKRFWHVW 
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DISCUSSION:  
 
Here, we show in a novel, enhanced passive-transfer model that daily passive transfer of IgG 
from patients with persistent CRPS to mice elicits intense, unilateral static mechanical 
hyperalgesia after hindpaw-injury, which remains stable through the experimental period. This is 
associated with increased paw edema that resolves over time. Collectively, these features 
resemble the course and pathophysiology of the clinical disease (1). In these extensive studies, a 
uniform pattern of transferred static mechanical hyperalgesia was seen in all patient preparations 
tested, highlighting that sero-negativity is unlikely to be common in patients with severe, 
persistent CRPS (31). 
This highlights the translational validity of the model and the importance of autoimmune 
mechanisms underlying the pathophysiology of both experimental and clinical CRPS. The 
stability and reproducibility of the transferred disease phenotype indicates the translational 
potential for this model to investigate the downstream mechanisms underpinning this type of 
chronic pain and to explore the efficacy of novel therapies. 
 
We found that the normal, post-traumatic inflammatory response in the incised paws rapidly 
declined, and fully settled by day 6-13 post incision, whereas the CRPS IgG-induced increase in 
paw hyperalgesia remained stable throughout the experimental period, with no correlation 
between these two parameters. Thus, unlike in the skin of some patients with clinical CRPS (21) 
where this does not correlate with the clinical signs (36), we found little evidence for any CRPS 
IgG related enhanced paw inflammation. Our results thus demonstrate that static mechanical 
hyperalgesia may not depend on persistent inflammatory mediator release, indicating that 
transferred CRPS (tCRPS) is not a model of enhanced post-traumatic inflammatory pain. There 
was however some evidence for abnormal production of two specific mediators in the CRPS 
group: substance P production was increased at early time points, in line with some clinical 
observations (13, 37) and with our earlier results (18), and there was also a mild, but significant 
bilateral increase in MCP-1 at day 13, the role of which will require further investigations. Our 
findings, that treatment with anakinra from day 8 fully resolved the tCRPS phenotype, and that 
the absence of microglial IL-ȕ did not fully protect from tCRPS suggest that persistent 
inflammatory reaction in other cells than microglia could at least partially sustain tCRPS. 
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In mice, the development of tCRPS remained restricted to the injured paw, consistent with the 
clinical situation, where about 90% of the cases show symptoms in only one, traumatised limb 
(23,25). The precise mechanisms through which circulating pathogenic IgG antibodies could 
mediate the regional post-traumatic CRPS are presently unclear. Early, transient trauma-induced 
inflammatory changes or regional opening of blood nerve and blood brain barriers may play a 
role by promoting the expression of neo-antigens, and providing IgG access to privileged sites 
(1). The presence of such facilitating mechanisms is supported by our in vivo imaging results 
which showed plasma leakage and increased myeloperoxidase (MPO) activity in the injured 
paw. 
MPO activity was variably enhanced in the CRPS group, without correlation with the extent of 
mechanical hyperalgesia or swelling. These findings may resemble the strong heterogeneity seen 
in patients, where the degree of limb swelling, colour changes, or temperature changes can 
markedly differ and WKHVHSDUDPHWHUVGRQ¶Wnecessarily correlate with perceived pain intensities, 
or recorded skin sensitivities (1). 
 
Since inflammatory changes in the paw did not appear to explain the increased mechanical 
hyperalgesia in the tCRPS mice, we investigated the potential role of glial responses in pain 
related neuronal circuits, which have been suggested to contribute to chronification processes in 
post-traumatic pain models (24, 39, 40). We found that tCRPS was associated with strong 
microglia and astrocyte activation at all three tested levels of the nociceptive pathway, the spinal 
cord dorsal horn, the periaqueductal grey and the contralateral somatosensory cortex. In the 
dorsal horn, the extent of enhancements in the CRPS- vs control groups were sometimes several-
fold higher than the extend of glia activation caused by the paw incision (Fig. 6), suggesting a 
powerful central effect of the transferred IgG. 
 
We hypothesized that perioperative anti-inflammatory interventions might block regional 
facilitatory perioperative factors required to render circulating CRPS autoantibodies pathogenic  
(3). To investigate whether such interventions could reverse the disease phenotype, we treated 
mice peri-traumatically with high-dose prednisolone. Prednisolone temporarily interrupted the 
process of autoantibody-dependent sensitisation, but did not abrogate it. Systemic steroids are 
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considered potentially effective in very early CRPS, based on the results of one preliminary trial 
(41). The present data suggest that where patients produce harmful autoantibodies, the peri-
traumatic application of steroids is unlikely to stop disease progression. In contrast, perioperative 
treatment with the IL-1 receptor antagonist anakinra consistently abrogated tCRPS-associated 
mechanical hyperalgesia. Notably, our results also indicated that there were only minor 
differences in the regional paw mediator environment after treatment with (ineffective) steroids 
and (effective) anakinra (Supplementary Fig. S8). Furthermore, even delayed blockade of IL-1 
actions with anakinra starting day 8 after the incision-trauma when trauma-induced peripheral 
inflammatory responses had largely resolved, was highly effective, calling into question our 
original hypothesis. 
 
IL-1 is a potent activator for astrocytes through actions via IL-1R1, whereas both activated 
microglia and astrocytes can contribute to painful central sensitisation though secreting IL-1 (42, 
43); these actions can be effectively blocked by anakinra (44±47). In our model, augmented 
dorsal horn glia cell activation in the tCRPS group was fully reversed by anakinra. Since IL-1-
mediated actions are involved in the cross-talk between neurons, microglia and astrocytes in 
promoting neuroinflammation (48, 49), we assessed glial IL-ȕ DQG ,/-Į SURGXFWLRQ LQ WKH
spinal cord and found that microglial IL-1ȕ production was increased on day 7 in the CRPS IgG 
treated group. In keeping with these data, we found that IL-Įȕ.2PLFHZHUH fully protected 
from developing the tCRPS phenotype, and associated glia cell activations. To assess the 
functional role of microglial IL-ȕ LQ&536-related hyperalgesia and swelling, we generated a 
novel mouse strain (IL-ȕfl/fl mice) enabling the deletion of IL-ȕ IURP PLFURJOLD Consistent 
with earlier data showing prolonged cre-dependent transgene expression in long-lived microglia, 
but not in peripheral macrophage populations with short turnover (29), tamoxifen treatment of 
Cx3cr1CreER x IL-1ȕfl/fl mice resulted in a marked reduction of microglial-, but not splenic, IL-ȕ
production. As seen in IL-1Įȕ .2 PLFH the absence of microglial IL-1ȕ production fully 
protected from tCRPS associated mechanical hyperalgesia up to day 3, but it had a markedly 
weaker effect thereafter. This highlights the importance of microglial IL-ȕLQthe tCRPS disease 
process, but also the likely involvement of other cells and/or IL-Į (48). Thus, further research 
will be needed to clarify respective contributions of peripheral versus central elements to the 
transferred disease phenotype, and the cellular targets of effective future medications. 
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Molecular mechanisms underpinning autoantibody pathogenicity in the model, and in the clinical 
disease may include IgG Fab binding to sensory nerves or nearby non-neuronal cells, with 
consequential changes to cellular functions without triggering a systemic inflammatory response 
(32). The latter mechanism has recently been demonstrated to underpin non-inflammatory joint 
pain in rheumatoid arthritis (32, 33). The target epitopes of CRPS IgG that elicit the pertinent 
changes in the model remain unknown.  Specific anti-autonomic autoantibodies are present in 
both early and late CRPS and may be involved in causing some tCRPS and clinical CRPS 
symptoms (34, 35). 
 
Study strengths include the robust, multi-dimensional evaluation of a novel, enhanced CRPS 
disease transfer model with preparations from patients whose clinical presentations differed, 
using outcomes designed to provide translational validity. Further, the comprehensive 
assessment of both peripheral, and central markers of immune activation and of several anti-
inflammatory treatments and gene knockout strategies, which has allowed a first informed 
suggestion for clinical studies with licenced drugs not previously reported in this patient group. 
 
Limitations of this study include the upper transfer limit cut-off at 13 days, which was necessary 
to avoid the adverse effects of serum sickness (50). However, LWPD\EHDUJXHGWKDWWKHµFKURQLF
SKDVH¶ LQ WKLV disease model starts from the second week after incision, when peripheral 
inflammation and symptoms in the control group resolve. As often observed with IgG disease 
transfer in other disease models, tCRPS does not fully match the symptoms of clinical CRPS 
(51). For example, overt motor dysfunction was not detected. Independently, results apply only 
to the sub-group of patients with persistent (6) Budapest CRPS and a high pain intensity (NRS 
>7), however this is also the group of patients which presents the most difficult situation in 
clinic:HFDQQRWH[FOXGHWKDWVRPHSDWLHQWVLQWKLVJURXSGRQ¶WKDYHWhese antibodies. However, 
since each of the 7 tested sera returned the abnormal phenotype (Figures 2 and S2), the 
likelihood that we have missed the absence of such antibodies in more than half of patients of a 
similar population appears very low (< 1%, MHWKRGV µSDWLHQWV¶ VHFWLRQ); the development of 
serum diagnostic tests will be required to clarify the proportion of sero-negative patients. 
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In summary, we have devised a robust translational model of DQ µLGLRSDWKLF¶ SRVW-traumatic 
chronic pain condition. The consistent pathogenicities of serum-IgG preparations indicate that 
amongst patients who have severe forms of this condition, autoantibody contribution is 
ubiquitous. Since abnormal signs were entirely confined to the injured side, we also established a 
general principle suggesting that pathogenic circulating autoantibodies can cause regionally-
restricted disease when triggered by local trauma. 
Our results support previous clinical observations that patients with persistent CRPS should 
respond to immune treatments with a reduction of at least some of their disease features (52). 
The clinical use of interleukin-1 receptor antagonists in CRPS has a broad therapeutic potential. 
Anakinra is safe, clinically licensed both in the US and Europe, and short-term use has an 
acceptable side effect profile (53, 54). Since CRPS regularly develops in the context of elective 
operations, such as arthroscopy or bunion surgery, prevention of such cases would have very 
important implications for both patients and procedure-related healthcare, as well as societal 
costs (55, 56).  Furthermore, in patients who will develop CRPS post-fracture trauma can often 
be identified early on by their high pain intensity (57, 58), and thus, early post-operative drug-
intervention may also be feasible (59). 
The effects of blocking IL-1 actions with anakinra when treatment is initiated at later time points 
after trauma, and the duration of the beneficial effects after the drug is withdrawn should now be 
investigated in the present experimental model. In addition, identifying the exact cellular targets 
for IL-1 actions in the pathophysiology of CRPS could facilitate the development of alternative 
IL-1 targeting approaches in the prevention or treatment of the disease. 
 
 
 
MATERIALS AND METHODS 
 
Patients and serum preparation 
Ethics permission was obtained to repeatedly sample larger volumes of additional CRPS patient 
sera (n=2), and healthy control sera (15/NW/0467, NorthWest Ethics Haydock, UK). Waste 
plasma was obtained between 2014-2017 from patients (n=5) newly undergoing plasma 
exchange treatment for persistent CRPS (20) at the Walton Center NHS Foundation Trust, a 
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tertiary care hospital in Northern England (UK). Use of waste-plasma does not require ethics 
committee approval; all patients provided individual written informed consent. 7KH SDWLHQWV¶
baseline characteristics are provided in the Table 1. We calculated the probability that we missed 
an event rate of >50% of patients having no pain-sensitising autoantibodies by (0.5 ^ (number of 
experiments x fraction of positive experiments)): 0.5 ^ 7= 0.008125, i.e. <1%. 
Small volumes of serum were pooled from samples taken at screening from all participants in a 
recent clinical trial (2) (n=7) who had baseline pain intensities of t 7/10. Their demographics and 
baseline characteristics are provided in the supplementary appendix, Table S1. The patients had 
provided written informed consent for the use of their serum samples for research purposes, as 
part of their overall consent for this study. 
 
IgG was prepared from plasma or serum of patients as previously described, using Protein G 
columns for affinity purification, followed by elution, buffering, dialysis in normal saline, and 
concentration to about 8 mg/ml immunoglobulin G for injection (pooled preparations 12mg/ml) 
(18). 
 
Table 1 
Number Sex/ age Limb/DD Pain  Budapest Type Plex 
#1 M/ 62 U/ 9 10 + II Y 
#2 F/ 37 L/ 15 7.5 + I N 
#3 F/ 38 L/ 10 9.5 + I Y 
#4 F/ 36 L/ 10 7 + I Y 
#5 F/ 40 L/ 5 7.5 + I Y 
#6 F/ 51 L/ 8 8 + I N 
#7 F/49 L/7 8 + I Y 
 
Table 1. Baseline characteristics of the patient serum donors. Age= age in years at the time of plasma/serum 
acquisition; Limb=affected limb, DD=disease duration in years, Pain=24h average pain intensity on a 11-point 
numeric rating scale (0-10, with 10=pain as bad as you can imagine), Budapest=Budapest research diagnostic 
criteria (new IASP criteria); Type= CRPS type, where II denotes with/I=without trigger injury to a major nerve, 
Plex=plasma derived from plasma exchange 
 
Animals 
Since CRPS affects women 2-3 times more frequent than men, experiments were carried out on 
female C57Bl/6 mice (10-12 weeks-old, 18-22 g). The original breeding pairs were purchased 
from Jackson Laboratories (USA) through Charles River Hungary. The animals were bred and 
 25 
kept in the conventional animal house of the Department of Pharmacology and Pharmacotherapy 
of the Medical School, University of Pécs at 24 °C, in a 12 h light±dark cycle and provided with 
standard rodent chow and water ad libitum. Mice were housed in groups of 5±10 in 
polycarbonate cages (330 cm2 floor space, 12 cm height) upon a bedding consisting of wood 
shavings. 
 
Animal ethics statement 
All procedures were performed according to the 1998/XXVIII Act of the Hungarian Parliament 
on Animal Protection and Consideration Decree of Scientific Procedures of Animal Experiments 
(243/1988), complied with the recommendations of the International Association for the Study of 
Pain. Ethical approval was given by the Ethics Committee on Animal Research of University of 
Pécs according to the Ethical Codex of Animal Experiments (licence No.: BA02/2000-31/2016). 
 
Experimental design 
After acclimatization and conditioning, 3 control measurements of nociception and paw volume 
were performed on days -4, -3, and -2µ'ay 0¶ was the starting day of intraperitoneal injections 
(Figure S8). Mice (5±7 per group) were treated daily with 1 ml of IgG fractions (8 mg/ml) 
obtained from CRPS patients or healthy volunteers, or saline. 
About 6 h after the injection on day 0, a standardized incision trauma was applied to the right 
hind-paw (see below). All mice removed their stitches within 16 hours post-surgery. 
Measurements (see below) were performed repeatedly, starting on day 1, until the respective 
termination day. 
Animals were sacrificed at various time-points (days 1, 2, 3, 6, 10, 13 post trauma), and tissue 
was harvested to analyse immunological alterations in the paw, and neurochemical changes in 
the central nervous system. Mice were deeply anesthetized with sodium-pentobarbital (100 
mg/kg i.p.) their hindpaws were harvested, frozen in liquid nitrogen, and kept at -80 °C for later 
analysis of tissue neuropeptides and cytokine production levels. Animals were then immediately 
perfused transcardially with PBS followed by 4% paraformaldehyde, and the whole brains and 
spinal cords were excised and prepared for further immunohistochemistry analyses. 
 
Plantar skin and muscle incision 
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To model a CRPS-triggering injury, we used the hindpaw plantar skin- muscle incision method 
under general anaesthesia as described earlier (18, 60). This model evokes a significant decline 
of the mechanonociceptive threshold, with a maximum 1 day after surgery, which persists for 7±
8 days. Briefly, mice were anesthetized with NHWDPLQH (?PJNJ &DO\SVRO *HGHRQ 5LFKWHU
3OF %XGDSHVW +XQJDU\ DQG [\OD]LQH (?PJNJ 6HGD[\ODQ (XURYHW $QLPDO +HDOWK %9
Bladel, Netherlands) on day 0. The operation site was prepared in a sterile manner, and the 
plantar surface of one right hindpaw was incised longitudinally, starting 0.2 cm from the heel, 
over a distance of 0.5 cm, intersecting the skin, fascia and plantar muscle. The skin was then 
opposed with interrupted stitches, using 5-0 nylon. The wound site was treated with povidone 
iodine solution. 
All measurements were carried out by two investigators (VT and NS), who were blinded to 
treatment-assignment. Blinding was performed by the technician who performed all injections 
EXWZKRZDVRWKHUZLVHQRWLQYROYHGLQWKHVWXG\µ6Ke differentially coded the animal cages and 
provided the decoding-NH\DIWHUFRPSOHWLRQRIWKHODVWPHDVXUHPHQWV¶ 
 
Determination of the mechanosensitivity of the paw 
Most patients with CRPS, have, in addition to their spontaneous pain, also pain with the 
application of pressure to the CRPS-DIIHFWHG OLPE µPHFKDQLFDO K\SHUDOJHVLD¶ (31), and all 
patients included into this study experienced this feature. The corresponding mechano-
nociceptive threshold of the plantar surface of the mouse hindpaw was determined with a 
dynamic plantar aesthesiometer (Ugo Basile 37400, Comerio, Italy) - a modified electronic von 
Frey technique-, as previously described (18, 61).  The blunt-end needle exerting an increasing 
force to the mouse paw provides a mild, but basically painful stimulus activating AG and C fibres 
(62). Threshold decreases are considered as mechanical hyperalgesia, and are expressed as 
percentage decrease of the mechano-nociceptive thresholds compared to the baseline values  
(63±65). 
 
Paw volume measurement 
Limb swelling is a common feature of CRPS-affected limbs, and all included patients reported 
intermittent limb swelling. Mouse-paw volume was measured using plethysmometry (Ugile 
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Basile Plethysmometer 7140, Comerio, Italy). Edema was expressed as a percentage increase 
compared to the baseline paw volume (65, 66). 
 
In vivo optical imaging of plasma leakage with indocyanin green extravasation 
The mechanisms underpinning CRPS IgG enhanced paw swelling are unknown, but one 
possibility is augmented plasma extravasation. Intravenously injected indocyanine green (ICG), a 
fluorescent cyanine dye, binds to plasma proteins and remains in the healthy vasculature. Under 
inflammatory conditions it can be used to evaluate capillary leakage. ICG (0.5 mg/ kg) was 
dissolved freshly in 5 w/v% aqueous solution of Kolliphor HS 15 and a macrogol-based 
surfactant (67), and injected intravenously (retrobulbar sinus) under ketamine ± xylazine 
anesthesia (100 mg/kg and 10 mg/ kg, i.p., respectively) two days after the paw incision. 
Fluorescence imaging was performed 20 minutes post injection, using a IVIS Lumina II in vivo 
optical imaging system 3HUNLQ(OPHU :DOWKDP 0$ 86$ DXWR DFTXLVLWLRQ WLPH IVWRS(? (?
ELQQLQJ(? (?H[FLWDWLRQ nm, emission filter: >800 nm). Identical Region of Interests (ROIs) 
were applied around both hindpaws up to ankles, and calibrated units of the luminescence (total 
radiance (total photon flux/s)) originating from the ROIs were analysed Fluorescence was 
H[SUHVVHGDVWRWDOUDGLDQWHIILFLHQF\>SKRWRQVVFPVU@>ȝ:FP@ (68). 
 
In vivo optical imaging of neutrophil myeloperoxidase (MPO) activity as a marker of 
cellular inflammation 
A luminol analogue chemiluminescent probe, L-012 (8-amino-5-chloro-7-phenylpyrido[3, 4-
d]pyridazine-1,4(2H,3H) dione; Wako Pure Chemical Industries Ltd, Japan) was used for in vivo 
visualisation of reactive oxygen and nitrogen species (ROS/RNS) produced by MPO in 
neutrophils and macrophages  (69, 70); L-012 has a high sensitivity towards ROS/RNS (71, 72). 
On days 2, 6 or 13 following incision, mice were anaesthetised by NHWDPLQH (?PJNJ
&DO\SVRO*HGHRQ5LFKWHU3OF%XGDSHVW+XQJDU\DQG[\OD]LQH(?PJ/kg; Sedaxylan, Eurovet 
Animal Health B.V., Bladel, Netherlands), hair was removed from both hind legs to prevent 
scattering/absorbing of the light signal. L-012 (?mg/kg) in sterile phosphate-buffered saline 
3%6(?PJPOZDV LQMHFWHG LS%LROXPLQHVFHQFHZDVPHDVXUHG(?PLQSRVW-injection using 
the IVIS Lumina II in vivo optical imaging system (PerkinElmer, Waltham, USA; 18(?V
aquisiWLRQ)VWRS(? (?%LQQLQJ(? (?). Data were analysed using Living Image® software (Perkin-
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Elmer, Waltham, USA). Identical Region of Interests (ROIs) were applied around both hindpaws 
up to ankles, and calibrated units of the luminescence (total radiance (total photon flux/s)) 
originating from the ROIs were analysed (73, 74). 
 
Measurement of sensory neuropeptides, inflammatory cytokines and nerve growth factor 
in the paw and cytokines in the plasma 
Pro-inflammatory neuropeptides, peripherally released from sensory nerves (75) and 
inflammatory cytokines released by peri-neuronal cells (21) are abnormal in some patients with 
CRPS, and we measured their concentrations in the model. 
The preserved frozen paws (see above) were thawed, chopped, and then homogenized in Triton 
X-100 and Calbiochem Protease Inhibitor Coctail containing Tris-HCl homogenisation buffer at 
0 °C. In every case, 400 µl homogenisation buffer was used for 50 mg tissue sample weight to 
normalise the difference of the sample size. The homogenate was centrifuged at 15,000-20000 g 
for 20 min at 4 °C and the supernatant was immediately removed for measuring inflammatory 
sensory neuropeptides and cytokines. We measured CGRP- and SP-like immunoreactivities in 
the paws by a sensitive radioimmunoassay techniques developed in our lab, which was 
previously described (18, 76, 77). 
Concentrations of IL-Į,/-ȕ,/-6, TNF-Į.&&;&/0&3-1, G-CSF, RANTES (CCL5), 
IFN-ȖIL-4 and IL-10 in mouse plasma and the paw homogenates were measured by cytometric 
bead array (CBA) as described (47, 78), using %' &%$ )OH[ 6HWV )UDQNOLQ /DNHV 1HZ
-HUVH\ 86$ DFFRUGLQJ WR WKH PDQXIDFWXUHUV¶ SURWRFRO 6DPSOHV ZHUH DFTXLUHG using a BD 
FACSVerse flow cytometer and data analysed by FCAP Array v3 software (BD Biosciences). 
Concentrations of nerve growth factor (NGF) and transforming growth factor beta (TGF-E) in 
the paw homogenates was measured by Sandwich ELISA kit (ChemiKineTM, Merck, Germany) 
according to the manufacturerV¶SURWRFRO. `The concentrations of all cytokines and chemokines 
were expressed as pg mediator per ml wet tissue homogenate (79). 
 
Paw skin light and electron microscopy 
 Following biopsy, samples were immersed into a fixative containing 2.5% glutaraldehyde 
buffered with phosphate buffer (PB, 0.1M, pH 7.4) for overnight at 4oC. Blocks then were fixed 
in 1% osmium tetroxide for 35 min and dehydrated with increasing concentration of ethanol. 
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After complete dehydration in ascending ethanol series blocks were transferred to propylene 
oxide before being placed into aluminum-foil boats and then embedded into gelatin capsule 
containing Durcupan resin (Sigma, Budapest, Hungary). 
 
Semithin and ultrathin sections were cut with Leica ultramicrotom. Semithin sections were 
mounted on glass slides, stained with toluidine blue and examined under light microscope. 
Ultrathin sections were mounted on collodion-coated (Parlodion, Electron Microscopy Sciences, 
Fort Washington, PA) single-slot copper grids, contrasted with uranyl-acetate and lead-citrate, 
and were examined in JEOL 1200EX-II electron microscope. 
 
Immunohistochemistry detection of central nervous system glia cells 
Brains and L4-L6 segments of the spinal cord were removed and post-fixed for 4 h in 4%  
paraformaldehyde before being placed into 30% sucrose (Duchefa Biochemie, Netherlands) in 
0.1 M PBS overnight at 4°C. Spinal cord and brain sections (30 µm) were prepared using a 
freezing microtome (Leica Biosystems Nussloch GmbH, Germany) as free floating sections (80, 
81). Sections were washed in 0.05M Tris buffered saline (TBS, pH 7.6), incubated in 0.3% 
H2O2/ methanol (Szkarabeusz Ltd, Hungary) for 30 min to inhibit endogenous peroxidase 
activity, followed by washing steps. Samples were incubated in primary antibodies for 48 hours 
at 4°C (GFAP dilution: 1:1000, NovocastraLeica Biosystems and Iba1; dilution: 1:500, Wako 
Chemicals GmbH, Germany). After washing steps, sections were incubated with Vectastain Elite 
ABC HRP Kit (Vector Labs, USA). The bound antibodies were visualized using Nickel (II) 
sulfate hexahydrate/ƍ-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich, USA) as 
chromogen, and glucose oxidase (Sigma-Aldrich, USA), which resulted in a black precipitate 
within the labelled cells. 
The sections were mounted onto gelatinized slides, allowed to dry overnight, dehydrated through 
increasing concentrations of ethanol; they were then coverslipped with DPX (Sigma-Aldrich, 
USA), and allowed to dry again. 
Three brain and spinal cord sections/mouse (n=3-4 animal/ group) were examined by 
Neurolucida software (v07, MBF Bioscience, USA) using Nikon Eclipse Ni-E bright field 
microscope with a computer controlled stage. The quantitative analysis was carried out using a 
modified unbiased stereology protocol as previously described (82). GFAP or Iba1 
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immunoreactive cells were examined in standardized areas of laminae I-II (superficial), and deep 
laminae of the dorsal horn of L4-L6 spinal cord sections, lateral periaqueductal grey matter, and 
the somatosensory hindpaw cortex (83, 84). 
Cell counting was conducted as follows: we traced the contours of the specific areas under low 
magnification (4x) with the help of Paxinos and Franklin mouse brain atlas (85), then we counted 
labelled astrocytes and microglia cells using higher magnification (10x). Since the thickness of 
the section was 30 µm, cells were counted in a 3-dimensional tissue and we calculated the 3D 
cellular volume using Neurolucida software. The density of GFAP and Iba1 immunopositive 
cells was determined as the number of counted cells divided by the volume of the measured area, 
expressed as cell number/ cm3 (86). 
  
Assessment of the preventive effect of peri-traumatic immune suppression  
We investigated whether early immune suppression would alter the disease course in the model. 
We administered the synthetic glucocorticoid prednisolone (4 mg/kg, i.p. (87, 88), or the IL-1 
receptor antagonist anakinra (10 mg/kg, i.p, Swedish Orphan Biovitrum AB (publ), SE-112 76 
Stockholm (89)). Control animals received respective vehicles. The first drug injection was 3 h 
prior to the plantar skin and muscle incision, and at least 4 h after IgG, or control treatment. 
Drug treatment was then repeated daily through the experimental period. 
 
Immunofluorescence 
25 ȝP WKLFN IUHH-floating brain sections were with 5% normal donkey serum and incubated 
overnight at 4C° with the appropriate mixture of primary antibodies: rabbit anti-P2Y12 (dilution 
1:500, #55043A, AnaSpec), goat anti-IL-Į dilution 1:500, #AF-400-NA R&D Systems), and 
goat anti-IL-ȕ dilution 1:500, #AF-401-NA R&D Systems). For visualization donkey anti-
rabbit Alexa 488 and donkey anti-goat Alexa 647 secondary antibodies (1:500) were used. 
Images were captured with a Nikon Ni-E C2+ (Nikon, Tokyo, Japan) confocal microscope, and 
image processing was performed using the NIKON NIS Elements Viewer 4.20 software 
(Auroscience Ltd., Budapest, Hungary). 
 
Generation of IL-1 beta floxed mice 
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Il1btm1a(EUCOMM)Hmgu embryonic stem cells (90) were purchased from the European Mouse 
Mutant Cell Repository (EuMMCR). Cells from clone HEPD0840-8-E03 were prepared for 
microinjection according to previously published protocol (91) with minor modifications. 
Briefly, ES cells were cultured in KO-DMEM + KOSR + 2i (MEK inhibitor and GSK3 
inhibitor) on a gelatinized (0.1% gelatin in PBS) cell culture dish maintained in standard culture 
conditions (37°C, 5% CO2, humidified). The culture medium was changed daily and the cells 
were passaged when 75-80% confluent using accutase to dissociate the cells. Cells were 
passaged no more than 3 times, and were transferred to media without 2i reagents for 24 hours 
prior to microinjection. Cells were then microinjected into 4 to 8 cell B6N-Tyrc-Brd/BrdCrCrl 
embryos. Surviving embryos were surgically implanted into the oviduct of day 0.5 post-coitum 
pseudopregnant mice. Resulting black/white C57BL/6N chimeras were back-crossed onto 
C57BL/6N wild-type mice to assess germline penetrance. Potential founder mice were screened 
by PCR for LacZ, Neo and LoxP sites. This line was further crossed with C57BL/6N-Tg(CAG-
Flpo)1Afst/Mmucd mice. The flp recombinase expression provided by this line resulted in a 
"conditional ready" (floxed) Il1btm1c(EUCOMM)Hmgu allele where exons 4 and 5 are flanked by loxP 
sites. 
 
Statistical analysis 
Data shown are means ± SEM, and two-way repeated measures ANOVA followed by 
%RQIHUURQL¶V post hoc test was used for comparison of threshold values between groups at 
respective timepoints. One-way ANOVA followed by Bonferroni's post hoc test was used for 
analysis of the immunochemistry and cytokine results. A value of p < 0.05 was considered 
statistically significant. 
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SUPPLEMENTARY APPENDIX: 
Figure S0 
 
 
Figure S0. Typical weight change over time. Minimal weight loss was observed in all groups reaching a nadir at 3-4 
days after surgery, followed by recovery. Values are in percent of baseline (the average of 3 measurements in the 
preceding week). Error bars denote SEM.   
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Table S1 
 
R-no Baseline 
P01002 6.8 
P01004 *9.3 
P01005 *8.2 
P01006 *8.4 
P01009 *7.2 
P01012 5.9 
  P01001 *7.6 
P01003 6.8 
P01007 6.6 
P01008 6.2 
P01010 *8.5 
P01011 *9.1 
 
Table S1. Pain intensities at baseline of all randomized patients in the MYPS trial, and of seven patients selected 
for pooled testing in the passive-transfer model. R-no= randomization number; baseline= pain intensity at baseline 
(average of daily average pain intensity ratings on a 0-10 numeric rating scale, during the screening period, 
maximally 14 entries); *denotes patients whose serum was used for a pooled experiment, see methods section 
µSDWLHQWVDQGVHUXPSUHSDUDWLRQ¶DQG)LJXUH6 G-H. Adapted from (58), Table W1. 
 
 
Figure S1 
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Fig. S1. Effect of serum IgG derived from complex regional pain syndrome (CRPS) patients or healthy controls, or 
saline on mechanical hyperalgesia (A) and swelling (B) of the intact hindpaw. Pooled results from the three long-
term experiments up to day 13 (injured-paw results: Figure 2). Data are means + SEM, *p < 0.05 (vs. saline-treated 
control mice), #p < 0.05 (vs. healthy IgG-treated mice); two-ZD\ $129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH
comparison test. 
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Figure S2 
 
Fig. S2. Behavioural effects of injection with CRPS/healthy serum-IgG samples not used in long behavioural 
experiments, and pooled samples from the MYPS trial. (A-F): effect of serum-IgG derived from complex regional 
 36 
pain syndrome patients #5-#7 (Table 1), or healthy controls, or saline on plantar incision-induced mechanical 
hyperalgesia and swelling; G-H: results from the injection of sera pooled from 7 patients (Table S1) with data are 
shown as means + SEM, *p < 0.05, ***p < 0.001 (vs. saline-treated control mice), ###p < 0.001 (vs. healthy IgG-
treated mice); two-way ANOVA followed by BonfeUURQL¶VPXOWLSOHFRPSDULVRQWHVW 
 
Figure S3 
 
 
 
Fig. S3 Correlation between mechanical hyperalgesia and paw swelling. Panels (A, B) show correlation between 
the mechanical hyperalgesia on day 6 and to paw edema on day 2 (when this was usually maximal), while (C, D) 
show correlations between both parameters on days 6 respectively. Dot plot data represent individual animal data, as 
obtained from 4-5 experiments using different patient preparations per time point, 6 mice/ experiment. There is no 
correlation at any measured time point. (A, B) n=30-32 animals; Spearman r=0.056; p= 0.741 in CRPS group and 
r=0.103; p=0.632 in healthy group. (C, D) n=24-26 animals; Spearman r=0.116; p=0.577 in CRPS group and 
r=0.202, p=0.331 in healthy group. 
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Figure S4 
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Fig. S4: Data of in vivo images of L-012 - derived bioluminescence for individual patient/healthy preparations on 
days 2 and 6. Data were obtained from animals treated with various serum-IgG preparations, or saline under general 
anaesthesia on days 2 and 6 after paw incision. Panel (A) shows results from patient #1 on day 2, (B) shows pooled 
results of 2 repeated experiments of patient #3 on day 2. Panels (C, D) represent the bioluminescence results of 
patient #1 and #4 on day 6, respectively. Data are means + SEM, of n= 6-12 mice/group *p < 0.05, **p < 0.01, ***p 
< 0.001 vs. respective control groups, #p < 0.05, ##p < 0.01, ###p < 0.001 vs. respective intact, one-way ANOVA 
IROORZHGE\%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW. 
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Table S2 
 
Day 2 animal 
number 
Day 6 animal 
number 
Day 13 animal 
number 
#1 7 #1 6 #4 6 
#3 6 #4 6 
  
#3 6 
 
 
  
total animal 
number 
19  12  6 
 
Table S2. Preparations and animal numbers for in vivo testing (corresponding Figures 4 and S4). 
 
Table S3 
Days 1 2 3 5 6 10 13 
#2      7c  
#1     7c   
#5   6c     
#3   6b,c     
#3 6c       
#3  6c      
#3     6c   
#3  6c      
#3     6b,c   
#3   6+     
#3   6b,c     
#3       6b,c 
#4   6c     
#4  6c      
#4     6b,c   
#3   7+     
#4       6b,c 
#4 6c       
#4     5+   
#4     6*   
#3     6*   
#3       6* b,c 
#4     6-6b,c   
#7    6c    
#6     6b,c   
#4 IL-Įȕ.2     6b,c   
Pooled serum     6c   
#8 M-IL-ȕ.2     4b,c   
#3 M-IL-ȕ.2     4b,c   
 
Table S3. List of experiments in the order in which they were done, with animal numbers per group. #1-
7=individual patient preparations used; +/* steroid/anakinra experiment; b sera were applied for central nervous 
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system (CNS) immunochemistry, c sera were used for behavioural assessment, and evaluation of the mediator levels 
only (no therapy). 
 
Figure S5  
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Figure S5 Effects of human IgG treatments and trauma on mediator concentrations in the hindpaws. Concentrations 
of (A) regulated on activation, normal T cell expressed and secreted (Rantes), (B) keratinocyte chemoattractant 
(KC), (C) granulocyte-colony stimulating factor (GCS-F), and (D) interleukin-1-alpha (IL-1Į) were measured by 
cytometric bead array from the same samples (CBA). Concentrations of (E) nerve growth factor (NGF) and (F) 
transforming growth factor beta (TGF-E were measured by Sandwich ELISA kit. 
Levels of interferon-gamma (IFN-ȖLQWHUOHXNLQ-4 (IL-4) and interleukin-10 (IL-10) were below the detection limit 
(not shown). Data are from 1-3 experiments with different patient preparations (brackets under the x-axis) per time 
point, 6 mice/ experiment. The preparations are specified in Table S2. Shown are means ± SEM; #p < 0.05, ##p < 
0.01, ###p < 0.001 vs. respective intact side, one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW. 
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Figure S6 
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Figure S6. Effects of human IgG treatments on mediator concentrations in mouse plasma. Concentrations of (A) 
TNF-Į, (B) IL-6, (C) IL-4, (D) MCP-1, (E) Rantes, (F) KC, (G) GCS-F, (H) IL-Į, (I) IL-1E, (J) IL-10 and (K) IFN-
Ȗ were measured by cytometric bead array (CBA) from the same plasma samples. Data are from 1-3 experiments 
(brackets under x-axis) with different patient preparations per time point, 6 mice/ experiment. Preparations used are 
specified in Table S4. Shown are means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 respective control groups, one-
ZD\$129$IROORZHGE\%RQIHUURQL¶VPXOWLSOHFomparison test. After correction for 10 tests, no significant result 
remained (not shown). 
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Figure S7 A 
 
 
 
Figure S7A. Representative photomicrographs and quantification of glia cells within the lateral periaqueductal 
grey matter. Panels (A-C) show GFAP immunopositivity indicating astrocytes, and panels (G-I) show Iba1 
immunopositivity indicating microglia cells ((A, G) saline, (B, H) healthy, (C, I) CRPS groups). The GFAP 
immunopositive sections shown are from day 6-, and Iba1 sections from day 13 after paw incision. Magnifications 
are 4x. Panels (D-F): quantification of astrocyte reactivity, and panels (J-L) microglia staining at 3, 6, and 13 days 
post hindpaw incision. Each panel represents the pooled results from 2 experiments with 2 different samples (#3, 
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#4). Shown are means ± SEM of 6-7 mice per group *p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control 
groups; one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPRGLILHGSRVWKRFWHVW 
 
 
Figure S7 B 
 
 
 
Figure S7B Somatosensory cortex glia cell staining. Quantification of astrocyte reactivity (M-O) and microglia 
staining (P-R) in somatosensory cortH[µ66&¶at 3, 6, and 13 days post hindpaw incision. Each panel represents the 
pooled results from 2 experiments with 2 different samples (#3, #4). Shown are means ± SEM of 6-7 mice per group 
*p< 0.05, **p< 0.01, ***p< 0.001 vs. respective control groups; #p< 0.05, ##p< 0.01, ###p< 0.001 vs. respective 
contralateral side; one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPRGLILHGSRVWKRFWHVW 
 
 
 
 
 
 
 
 
 
 
 
Figure S8 
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Figure S8. Effects of steroid and anakinra treatment on inflammatory cytokine concentrations in the hindpaws on 
day 3. (A) TNF-Į, (B) IL-6, (C) MCP-1, (D) Rantes, (E) KC, (F) GCS-F, (G) IL-1D, (H) IL-1E were measured by 
cytometric bead array (CBA) from the same plasma samples. Other cytokines (IL-4, IL-10 and IFN-ȖZHUHXQGHU
detection limit. Data are from 2 experiments (brackets under x-axis) with different patient preparations per time 
point, 6 mice/ experiment (Table S3). Shown are means ± SEM; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. respective 
intact side, one-ZD\$129$IROORZHGE\%RQIHUURQL¶VPXOWLSOHFRPSDULVRQWHVW. 
 
 
 
 
 
Figure S9 
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Figure S9. Generation of IL-1bfl/fl  mice. A) Genetic targeting shows exon 4-5 flanked with loxP sites, positioned 
upstream of a lacZ/Neo resistance cassette, which is excised upon Flp recombination, resulting in the generation of 
IL-1bfl/fl allele. Cre recombinase leads to exon 4-5 deletion, generating cell-specific IL-1E KO mice. B) Genotyping 
PCR showing amplification of the WT (480bp) and IL-1E floxed allele (673bp).  
 
 
 
 
 
 
 
 
 
 
Figure S10 
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Figure S10. Microglia, but not splenic macrophages derived from tamoxifen-treated Cx3cr1CreER x IL-1ȕfl/fl mice 
show elimination of IL-ȕ. Microglia and splenic monocytes/macrophages were isolated by magnetic separation 
using anti-CD11b microbeads after 12h after priming with intraperitoneal LPS administration, in vivo. IL-ȕOHYHOV
were measured by cytometric bead array and values expressed as pg/mg following correction for protein content. 
Note that only microglia but not spleen cells show a reduction in IL-ȕOHYHOVFRQILUPLQJWKHVSHFLILFHOLPLQDWLRn of 
IL-ȕIURPPLFURJOLD 
 
Figure S11 
 
Figure S11. Scheme of the experimental paradigms and investigational techniques. i.p. intraperitoneally; IgG 
immunoglobulin G, black arrows indicate the time of sample harvesting for central nervous system (CNS) 
immunochemistry, paws were also harvested on days 1,2, and 10.  
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